San Francisco, 16
November 2018: The global huntington’sdisease treatment market size is expected to be valued at
USD 1.5 billion by 2023, as per a new report by Grand View Research, Inc.,
registering a CAGR of 38.2% during the forecast period. The market is largely
driven by factors such as rapid uptake of disease-modifying therapies,
increased adoption of novel therapeutics, and increase in R&D activities.
Huntington’s disease is an inherited
neurodegenerative disorder characterized by a combination of motor, cognitive,
and psychiatric symptoms. Currently, only two symptom-alleviating therapies are
specifically approved for this disorder: Xenazine and Austedo. Off-label
medications are used extensively due to lack of approved alternatives.
The pipeline for Huntington’s disease is
expected to witness rapid developments in the coming years as disease-modifying
drugs transform the market landscape. Improved disease understanding has led to
significant progress in the development of therapeutic approaches aimed at
modifying specific changes linked to the causative mutation. The potential role
of RNA antisense technology and stem cell therapy are under active clinical
investigation. Wave Life Sciences and Ionis Pharma’s antisense oligonucleotides
aim to target underlying disease cause and are expected to contribute
significantly to market growth.
Access
Research Report of Huntington’s Disease
Treatment Market @ www.grandviewresearch.com/industry-analysis/huntingtons-disease-treatment-market
Further
key findings from the report suggest:
· Teva is projected to become the market
leader, capturing more than 45% of the market in 2023, driven by Austedo’s
rapid uptake and improved efficacy profile compared to its competitors. Teva’s
Huntexil is expected to be the only new symptom-alleviating drug to be launched
during the forecast period
· Raptor’s RP103 is expected to face
head-to-head competition from Prana Biotech’s Phase II drug PBT2 to be the
first disease modifying therapy to be launched in the market
· Currently, 23 products are under clinical
investigation for Huntington’s disease, out of which, one is in Phase II/III
each, thirteen in Phase II trials, two in Phase Ib/IIa, six in pre-clinical
trials, and one in discovery phase
· EU5 will remain the second largest market
with more than 15% share in 2023, driven by rising disease prevalence, novel
drug launches, and increase in R&D activities
· Companies are now focusing on development
of treatments that can be injected directly in the brain to directly inhibit
the formation of mutant HTT protein, instead of targeting the mutant protein
· Drugs with novel targets in early-phase
development include Stealth Biotherapeutics’ SBT-20 (mitochondria-targeted
cytoprotective peptide), Cellavita + Azidus Brazil’s Cellavita HD (stem cell
therapy), Sangamo/ Shire’s mHTT ZFP (zinc finger protein), and UniQure’s
AMT-130 (gene therapy).
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global Huntington’s disease treatment market based on treatment:
Huntington’s Disease Treatment Outlook
(Revenue, USD Million, 2017 - 2023)
·
Symptomatic therapy
·
Disease-Modifying therapy
Huntington’s Disease Treatment Country
Outlook (Revenue, USD Million, 2017 - 2023)
·
U.S.
·
U.K.
·
France
·
Germany
·
Italy
·
Spain
·
Japan
Access Press Release of
Huntington’s Disease Treatment Market@ www.grandviewresearch.com/press-release/global-huntingtons-disease-treatment-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment